Tracking Candida auris
March 7, 2019: Case Count Updated as of January 31, 2019
Candida auris is an emerging fungus that presents a serious global health threat. C. auris causes severe illness in hospitalized patients in several countries, including the United States. Patients can remain colonized with C. auris for a long time and C. auris can persist on surfaces in healthcare environments. This can result in spread of C. auris between patients in healthcare facilities.
Most C. auris cases in the United States have been detected in the New York City area, New Jersey, and the Chicago area. Strains of C. auris in the United States have been linked to other parts of the world. U.S. C. auris cases are a result of inadvertent introduction into the United States from a patient who recently received healthcare in a country where C. auris has been reported or a result of local spread after such an introduction.
Candida auris was made nationally notifiable at the 2018 Council for State and Territorial Epidemiologists (CSTE) Annual Conference. For the updated case definition and information on the nationally notifiable condition status, please see the 2018 CSTE position statement Cdc-pdf[PDF – 16 pages]External.
Cases reported prior to 2019 are categorized by the state where the specimen was collected. Cases reported in 2019 are categorized by the patient’s state of residence to reflect the standards of the Nationally Notifiable Disease Surveillance System. Most probable cases were identified when laboratories with current cases of C. auris reviewed past microbiology records for C. auris. Isolates were not available for confirmation. Early detection of C. auris is essential for containing its spread in healthcare facilities.
Clinical cases of Candida auris reported by U.S. states, as of January 31, 2019
|State||Number and type of clinical Candida auris cases reported|
Beyond the clinical case counts reported above, an additional 1020 patients have been found to be colonized with C. auris by targeted screening in seven states with clinical cases.
CDC will update case counts monthly.
Cases are classified according to definitions established by the Council of State and Territorial Epidemiologists Cdc-pdf[PDF – 13 pages]External. Clinical cases are based on cultures or culture-independent diagnostic testing from specimens collected during the course of clinical care for the purpose of diagnosing or treating disease. Confirmed clinical cases are those with isolates that have been confirmed as C. auris in the laboratory.
Cases are classified according to definitions established by the Council of State and Territorial Epidemiologists Cdc-pdf[PDF – 13 pages]External. Probable clinical cases are those with presumptive laboratory evidence and evidence of epidemiologic linkage (e.g., Candida haemulonii identified in a patient from a facility with other known C. auris cases, but the isolate was not available for confirmatory testing or has not yet undergone further testing).
Certain laboratory methods commonly misidentify C. auris. Most frequently, C. auris is misidentified as C. haemulonii, though other misidentifications have occurred. CDC has developed identification, treatment, and infection control recommendations to help prevent the spread of C. auris.
Cases are classified according to definitions established by the Council of State and Territorial Epidemiologists Cdc-pdf[PDF – 13 pages]External. Screening is when swabs are collected from patients to determine whether or not they may unknowingly be carrying the organism somewhere on their bodies without signs of active infection. Colonization means that these patients are found to be carrying C. auris on their bodies, even though they are not sick with the infection. This targeted screening work was conducted as part of an effort to control the spread of C. auris.
CDC encourages all U.S. laboratories that identify C. auris to notify their state or local public health authorities and CDC at email@example.com. CDC is working closely with public health and healthcare partners to prevent and respond to C. auris infections. The CDC-sponsored Antibiotic Resistance Laboratory Network (ARLN) will help improve detection and response to C. auris nationwide.
- Single cases of C. auris have been reported from Austria, Belgium, Iran, Malaysia, the Netherlands, Norway, Russia, Switzerland, Taiwan, and the United Arab Emirates.
- Multiple cases of C. auris have been reported from Australia, Canada, China, Colombia, France, Germany, India, Israel, Japan, Kenya, Kuwait, Oman, Pakistan, Panama, Saudi Arabia, Singapore, South Africa, South Korea, Spain, the United Kingdom, the United States (primarily from the New York City area, New Jersey, and the Chicago area) and Venezuela; in some of these countries, extensive transmission of C. auris has been documented in more than one hospital.
- U.S. cases of C. auris have been found in patients who had recent stays in healthcare facilities in India, Kenya, Kuwait, Pakistan, South Africa, the United Arab Emirates, and Venezuela, which also have documented transmission.
- Other countries not highlighted on this map may also have undetected or unreported C. auris cases.